Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

NIH 2NETWORK 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 166Carboplatin 132Cisplatin 81Paclitaxel 78Gemcitabine 77Pemetrexed 72Bevacizumab 63Docetaxel 54Fluorouracil 49Oxaliplatin 48Dexamethasone 46durvalumab 43atezolizumab 39Leucovorin 39130-nm albumin-bound paclitaxel 39Capecitabine 37Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Prednisone 28Lenalidomide 28enzalutamide 27pomalidomide 25Letrozole 25Irinotecan 25daratumumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × fluciclovine F-18 × 30 days × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡